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Abstract
Background: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer
patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wild-
type p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status
together with MDM2 SNP309 genotype in stage III breast cancer patients receiving paclitaxel or epirubicin monotherapy.
Experimental Design: Each patient was randomly assigned to treatment with epirubicin 90 mg/m
2 (n=109) or paclitaxel
200 mg/m
2 (n=114) every 3rd week as monotherapy for 4–6 cycles. Patients obtaining a suboptimal response on first-line
treatment requiring further chemotherapy received the opposite regimen. Time from last patient inclusion to follow-up
censoring was 69 months. Each patient had snap-frozen tumor tissue specimens collected prior to commencing chemotherapy.
Principal Findings: While TP53 and CHEK2 mutations predicted resistance to epirubicin, MDM2 status did not. Neither TP53/
CHEK2 mutations nor MDM2 status was associated with paclitaxel response. Remarkably, TP53 mutations (p=0.007) but also
MDM2 309TG/GG genotype status (p=0.012) were associated with a poor disease-specific survival among patients having
paclitaxel but not patients having epirubicin first-line. The effect of MDM2 status was observed among individuals
harbouring wild-type TP53 (p=0.039) but not among individuals with TP53 mutated tumors (p.0.5).
Conclusion: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy. In contrast, TP53
mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary
paclitaxel but not epirubicin monotherapy.
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Introduction
Anthracyclines and taxanes are the chemotherapeutic agents
most frequently used in patients with primary as well as metastatic
breast cancer. So far, we have a limited understanding of the
mechanisms conferring chemoresistance to both drugs in vivo, and
we lack suitable predictive factors to select optimal therapy.
Previously, we [1,2,3] and others [4] have reported mutations in
the TP53 gene (encoding the tumor suppressor protein p53), with
mutations affecting the DNA-binding domains L2/L3 of p53 in
particular, to be associated with resistance to anthracyclines in
breast cancer patients. While in vitro studies have provided
conflicting data suggesting a role of p53 to taxane sensitivity
[5,6], the result from the only clinical study available evaluating
TP53 status with respect to paclitaxel sensitivity revealed no
correlation [4].
MDM2 (Mouse Double Minute 2 homolog) is an important
regulator of p53 and function by suppressing p53 transcriptional
activity [7]. Further, MDM2 amplifications and over-expression
have been considered an alternative mechanism of p53 inactiva-
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polymorphism (SNP) 309 T.G in the MDM2 intronic promoter
(rs=2279744, referred to as SNP309 in this paper) was found
associated with increased MDM2 mRNA and protein levels [9].
Subsequently, conflicting evidence has linked the SNP 309G
variant to enhanced risk of different cancer forms [10]. The
predictive value of TP53 and CHEK2 mutations on response to
chemotherapy in the epirubicin arm of this study has previously
been reported [3]. Here, we report the effect of TP53 and CHEK2
mutation status on response to paclitaxel. Further, we report the
predictive value of MDM2 SNP309 genotype on response to
epirubicin as well as paclitaxel treatment together with long-term
follow-up data with respect to disease-specific survival (DSS) for
patients in both arms up to a cut-off day 5 year 8 months after the
final date of randomization.
Materials and Methods
Ethics Considerations
The study protocol was approved by the Regional Ethical
Committee (Norwegian Health Region III), including formal
Biobank registration in accordance to Norwegian law. The study
and protocol is registered under the Norwegian Social Science
Data services ((www.nsd/uib/personvern/database/), University
of Bergen project no 16297 and Helse Bergen project no 13025).
Each patient gave written informed consent.
Patients
This study enrolled a total of 223 patients with primary stage III
breast cancers. Recruitment period was between November 24,
1997 and December 16, 2003. The median age was 51 years
(range 25–70). Forty-two patients had a T4 tumor, 177 patients
had T3, while three patients had a T2 tumour with concomitant
N2 lymph node metastases. One patient was erroneously enrolled
with stage II disease. Twenty-four (T3/T4) patients had limited
distant metastases (Table 1); these patients were included in the
response analysis but omitted from the relapse-free (RFS) and
disease-specific survival (DSS) analysis.
Treatment Protocol
This was an open-labelled multicenter study in which patients
were randomly allocated to treatment with paclitaxel (n=114) or
epirubicin (n=109) monotherapy. The reason for randomizing
patients between the two arms was not to compare anti-tumor
efficacy of the two regimens but to balance patients in the two
treatment cohorts with respect to pre-treatment characteristics.
The two regimens contained either paclitaxel 200 mg/m
2 or
epirubicin 90 mg/m
2 administered at 3 week intervals. Treatment
was scheduled for four cycles with a possibility for extension based
on clinical decisions (see Treatment Protocol uploaded under
Supporting Information for details; Protocol S1). Patients
obtaining a suboptimal response or progressing on first-line
treatment were switched to the opposite regimen in case they
were determined to be in need of additional chemotherapy by the
treating physician.
All patients harbouring oestrogen receptor (ER) positive tumors
(n=125) were given tamoxifen for 5 years except for postmeno-
pausal patients who were on tamoxifen treatment up to the
summer of 2004 and subsequently, were switched to 3 years on
treatment with an aromatase inhibitor after completing 2–5 years
on tamoxifen treatment (Norwegian Breast Cancer Group
Guidelines; www.nbcg.no).The difference in outcome between
patients having 5 years on tamoxifen and those switching to an
aromatase inhibitor (postmenopausals having received 2 years +
on tamoxifen after 2004, but none of the patients having
completed 5 years on tamoxifen at that time); is that small that
we do not anticipate to see any difference in outcome in a trial of
this size.
Response evaluation
Clinical response was assessed before each treatment cycle.
Because the protocol was implemented by October 1997, responses
were graded by the UICC system [11]. For consistency, we decided
to keep this classification and not change to the recent ‘‘RECIST’’
criteria [12] in the middle of the study period. Thus, responses were
classified as; Complete Responder (CR) (complete disappearance of
all tumor lesions), Partial Responder (PR) (reduction $50% in the
sum of all tumor lesion, calculated for each lesion as the product of
the largest diameter and the one perpendicular to it), Progressive
Disease (PD) (increase in the diameter product of any individual
tumor lesion by $25%), and Stable Disease (SD) (anything between
PR and PD). To analyze for the predictive value of the different
parameters, similar to what we conducted in previous studies (2,17),
we compared PD tumors to the combined group of SD/PR/CR
tumors [2,13].
Tissue sampling
Before commencing chemotherapy, each patient had an
incisional tumor biopsy as previously described [1]. All tissue
samples were snap-frozen in the operating theatre immediately on
removal. For patients switching to the alternative treatment
option, a snap-frozen tru-cut biopsy was collected prior to
commencing treatment with the second-line drug regimen. Finally,
snap-frozen tissue was collected at surgery (mastectomy).
DNA Purification
Genomic DNA from tumor biopsies was isolated using QIAmp
DNA Mini kit (Qiagen, Chatsworth, CA) according to the
manufacturer’s protocol.
TP53 analysis
All TP53mutational analyses were performed blinded to clinical
data. The complete coding region of TP53 (NM_000546) was
sequenced as previously described [3]. Since normal tissue
(required for LOH analysis) was available from 86 patients only,
a gene copy number analysis was performed by quantitative PCR
using hydrolysis probe-assays (LightCycler 480 system; Roche).
Duplex reactions amplifying the genomic area of interest and the
Beta-2-microglobulin as an internal reference were performed.
(Details regarding primers and PCR conditions are available as
Supporting Information; Method S1). Data obtained through the
TP53 specific reactions were normalized by adjusting for Beta-2-
microglobulin levels. These normalized values were divided by the
corresponding values from a reference sample (pooled DNA from
.10 healthy donors). Samples were considered to have reduced
copy number if the sample/reference ratio was ,0.75, and
increased copy number if the ratio was .1.25.
CHEK2 analysis
All CHEK2 mutational analyses were performed blinded to
clinical data. The complete coding region of CHEK2 (NM_
007194) was sequenced as previously described [3].
MDM2 promoter screening
A region of the MDM2 (AF_527840) promoter was amplified
using the DyNazyme EXT polymerase system (FINNZYMES)
according to the manufacturer’s instructions with primers
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Clinicopathological factors Epirubicin cohort Paclitacel cohort Total
n=109 n=114 n=223
Median age at diagnosis 51 (range 28–70) 50 (range 25–70) 51(range 25–70)
Response
CR 3 (2.8%) 5 (4.4%) 8 (3.6%)
PR 50 (45.9%) 45 (39.5%) 95 (42.6%)
StD 44 (40.4%) 44 (38.6%) 88 (39.5%)
PD 10 (9.2%) 12 (10.5%) 22 (9.9%)
Missing 2 (1.8)% 8 (7.0%) 10 (4.5%)
Tumor size
T2 2 (1.8%) 1 (0.9%) 3 (1.3%)
T3 92 (84.4%) 85 (74.6%) 177 (79.4%)
T4 14 (12.8%) 28 (24.6%) 42 (18.8%)
T5* 1 (0.9%) 1 (0.4%)
Lymph node
N0 47 (43.1%) 42 (36.0%) 89 (39.9%)
N1 45 (41.3% 57 (50.0%) 102 (45.7%)
N2 15 (13.8%) 15 (13.2%) 30 (13.5%)
N3 1 (0.9%9 1 (0.4%)
N4 1 (0.9%) 1 (0.4)
Distant metastatis
M0 99 (90.8%) 100 (87.7%) 199 (89.2%)
M1 10 (9.2%) 14 (12.3%) 24 (10.8%)
Oestrogen receptor
Positive 59 (54.1%) 66 (57.9%) 125 (56.1%)
Negative 48 (44.0%) 45 (39.5%) 93 (41.7%)
Missing 2 (1.8%) 3 (2.6%) 5 (2.2%)
Progestron receptor
Positive 52 (47.7%) 52 (45.6%) 104 (46.6%
Negative 56 (51.4%) 58 (50.9%) 114 (51.1%)
Missing 1 (0.9%) 4 (3.5%) 5 (2.2%)
Disease specific dead after 6 years follow-up 42 (38.5%) 48 (42.1%) 90 (40.4%)
Median BMI 26.2 (range 19.3–48.4) 25.4 (range 17.6–41.2) 25.5 (17.6–48.4)
TP53 mutations
All mutations 23 (21.1%) 25 (21.9%) 48 (21.5%)
Mutations in L2/L3 domain 12 (11.0%) 12 (10.5%) 24 (10.8%)
TP53 LOH
WT 72 (67.3%) 51 (45.1%) 123 (55.9%)
LOH 35 (32.7%) 62 (54.9%) 97 (44.1%)
Missing 2 1 3
TP53 Arg72Pro (rs1042522)
GG 77 (70.6%) 77 (67.5%) 154 (69.0%)
GC 26 (23.9%) 27 (23.7%) 53 (23.8%)
CC 6 (5.5%) 10 (8.8%) 16 (7.2%)
MDM2 SNP309 (rs2279744)
TT 36 (34.0%) 43 (39.5%) 79 (36.7%)
TG 56 (52.8%) 54 (49.5% 110 (51.2%)
GG 14 (13.2%) 12 (11.0%) 26 (12.1%)
Missing 3 5 8
CHEK2 mutations 3 (2.75%) 3 (1.4%) 6 (2.7%)
*One patient was erroneously enrolled with stage II disease.
doi:10.1371/journal.pone.0019249.t001
Predictive and Prognostic Impact of TP53 and MDM2
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19249MDM2PF-CGGGAGTTCAGGGTAAAGGT and MDM2PR-AGCA-
AGTCGGTGCTTACCTG. Thermocycling conditions were an
initial step at 94uC, 40 cycles at 94uC for 1 min, 59uC for 30 s
and 72uC for 1 min, followed by a final step at 72uC for 7 min.
PCR product were sequenced using Big Dye terminator mixture
(Applied Biosystems). All sequencing reactions were carried out
with the same primers as used for PCR amplification. After an
initial step of 5 min denaturation at 94uC, the sequencing reaction
was carried out for 40 cycles of 10 s at 94uC, 5 s at 55uC and
4 min at 60. Capillary gel electrophoresis, data collection and
sequence analyses were performed on an automated DNA
sequencer (ABI 3700).
Statistical Analysis
All statistical calculations were performed using the SPSS
version 15 software package. The differences in the distribution of
TP53 mutations and MDM2 SNPs among patients revealing a PD
and the responders were analyzed using the Fisher’s exact test. P-
values reported for Fisher’s exact tests are given as two-sided and
cumulative. Survival analyses were performed by Kaplan-Meier,
and subsets of patients were compared using the log-rank test.
Patients harbouring distant metastases at the time of diagnosis
were excluded from the survival analysis. Deaths for reasons other
than breast cancer were treated as censored observations. To
explore the effects of several variables and their combined effects
on DSS, multivariate Cox regression models were used.
Results
TP53, CHEK2 mutations and MDM2 status in the patient
cohort
Eight patients in the paclitaxel arm and two patients in the
epirubicin arm could not be evaluated for treatment response,
mainly due to early termination of therapy because of side effects.
These patients were included in the RFS and DSS analysis on an
intention-to-treat basis. Patients harbouring limited distant
metastases in addition to their locally advanced disease at
diagnosis (n=24) were eligible for response assessment but omitted
from the RFS and DSS analysis. Thus, 106 and 107 patients were
evaluable for treatment response while 100 and 99 patients were
included in the overall survival analysis from the paclitaxel and
epirubicin arms, respectively.
Clinical stage at diagnosis, objective response rates and major
biological findings are summarized in Table 1. TP53 mutations
were identified in 48 (21.5%) of the patients (Table 1); the 23
mutations in the epirubicin cohort has previously been reported [3]
but the 25 mutations in the paclitaxel cohort have not been
presented earlier (see details regarding individual mutations
in Supporting Information Table S1). Out of a total of 48
mutations, 42 were missense, four nonsense and two deletions.
Twenty-four of the mutations; 12 in the epirubicin cohort and 12 in
the paclitaxel cohort, directly or indirectly affected the L2/L3
domains of the p53 protein critical to DNA binding [14], previously
found to predict a poor prognosis in general [15] and drug
resistance to anthracyclines and mitomycin in particular [1,2].
Normal tissue (WBC) from 39 patients was available for
germline characterization, revealing two missense mutations to
be germline (codon 254 and codon 347; Supporting Information
Table S1). Overview regarding the p53 Arg72Pro polymorphism
(rs 1042522) and TP53 LOH status is presented in Table 1.
While three patients in the paclitaxel cohort harboured CHEK2
mutations (two patients; Arg117Gly, one patients; Ile157Thr) each
obtained a PR to treatment. Based on previous characterization
[3], these mutants revealed partial agonistic functions.
MDM2 SNP309 data were available from 215 out of 223
patients (eight patients were not informative). Seventy-nine
patients (36.7%) revealed the TT genotype, 110 (51.2%) displayed
a TG genotype and 26 (12.1%) were found to hold the GG
genotype (Table 1). The polymorphism was shown to be in Hardy-
Weinberg equilibrium.
Notably, no pairwise correlation between TP53 mutation status,
the p53 Arg72Pro variant or the MDM2 SNP309G polymorphism
was observed.
Correlations between TP53 and MDM2 status and
response to epirubicin or paclitaxel therapy
The influence of TP53 and CHEK2 status on response to
treatment with epirubicin has been reported previously [3].
Paclitaxel responses in relation to individual mutations are
presented in Supporting Information Table S1. While TP53
mutations, in particular those affecting the L2/L3 domains but
also CHEK2 non-sense mutations, previously shown to be devoid
of Chk2 activity [3], predicted lack of response to anthracycline
treatment [3], MDM2 promoter genotypes were not associated
with response to epirubicin either in the total cohort (n=107)
(p.0.5) or in the subgroup (n=84) of patients revealing wild-type
TP53 status (p.0.5).
Neither TP53 mutations in general nor mutations affecting the
L2/L3 domains were associated with lack of response to paclitaxel
treatment (Table 2).
No association between TP53 LOH status, the Arg72Pro
polymorphism or MDM2 genotype status and response to either
epirubicin or paclitaxel treatment was recorded (p.0.25).
Tumor tissues obtained after paclitaxel treatment (without any
addition of epirubicin) was available from five out of 25 patients
harbouring TP53 mutations. Out of these patients, two (Tax260
and Tax106) had SD, while three (Tax086, Tax192 and Tax056)
revealed progressive disease. Interestingly, TP53 mutation status
did not change during therapy in any of these patients (Supporting
Information Table S1).
Response to second-line chemotherapy
Forty-one (38.7%) patients obtaining a suboptimal response to
paclitaxel and thirty patients (28%) obtaining a suboptimal
response to epirubicin received second-line treatment with the
opposite regimen. Lack of cross-resistance between anthracyclines
and taxanes have been confirmed in multiple studies [16,17]; thus,
potential salvage by second-line therapy may have significant
influence on subsequent relapse-free as well as disease-specific
survival, masking a potential correlation between response to first-
line treatment and RFS and/or DSS. Characteristics of those
patients receiving second-line treatment (including response to
first- as well as second-line treatment, together with TP53
mutation status) are depicted in Supporting Information Table
S2. Comparing response to epirubicin and paclitaxel administered
as second-line versus first-line treatment (Table 3), the frequency of
patients obtaining a PD was similar in both settings. However, the
likelihood of having a CR/PR on second-line therapy was
significantly lower as compared to response to first-line therapy
with respect to epirubicin (p=0.028) as well as to paclitaxel
(p=0.022), consistent with the general observation of lower
response rate to second- as compared to first-line therapy in
metastatic disease.
TP53 genotypes and breast cancer survival
No difference with respect to RFS or DSS was observed
between the two treatment cohorts (p.0.5; Figure 1A). TP53
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DSS (p=0.084; Figure 1B) but did not influence RFS (p=0.337)
when the two cohorts were analyzed together. The reason for
analyzing both cohorts together was to test for a general prognostic
effect independent of type of systematic therapy [18]. The
difference in DSS was smaller if patients harbouring TP53
mutations affecting the L2/L3 domain were compared to the
combined group of patients revealing TP53 wild-type status or
TP53 mutations outside the L2/L3 domain (p.0.5). Stratifying
patients according to treatment, TP53 mutations were associated
with a significant reduction in DSS (p=0.007) and a non-
significant (p=0.140) reduction in RFS among patients treated
with paclitaxel (Figure 1C) but not among patients receiving
epirubicin treatment upfront (Figure 1D). Interestingly, this
association for DSS became non-significant when tumors
harbouring TP53 mutations affecting the p53 L2/L3 DNA-
binding domains were compared to those with wild-type or TP53
mutations outside the L2/L3 domains (p=0.095).
Notably, patients harbouring TP53 mutations revealed a non-
significant trend for an inferior RFS and DSS if treated with
paclitaxel as compared to epirubicin as first-line treatment. While
patients harbouring wild-type TP53 tumors did marginally better
on paclitaxel (Supporting Information Figure S1), a test for
interaction between treatment regimen and TP53 status with
respect to DSS revealed no significant difference (p=0.165).
To test for potential confounding effects of second-line therapy
on DSS, we analysed for DSS excluding all patients having
second-line chemotherapy with the alternate drug. Excluding
patients having second-line therapy from the DSS analysis had
no major effects on outcome (DSS paclitaxel; p=0.011;
epirubicin; p=n.s.).
MDM2 genotypes and breast cancer survival
We then investigated the association between the MDM2
SNP309 genotypes and breast cancer survival. In the first part of
the analysis we compared all three groups (309TT, 309TG and
309GG). Due to a small number of patients harbouring the
SNP309GG genotype, similar to other studies [19,20] we
compared the combined group of individuals harbouring the
309GG and 309TG genotypes versus 309TT.
Taking both patient cohorts together, no difference with respect
toRFS(p=0.261)wasobservedbetweenMDM2SNP309promoter
genotypes. However, a significant correlation was found between
MDM2SNP309 promoter genotypes and DSS (p=0.045).This was
also the case for the sub-cohort of patients harbouring wild-type
TP53 (RFS; p=0.138, DSS; p=0.027, Figure 2A).
Combining patients harbouring the SNP309 TG and GG
genotypes from both treatment cohorts, these patients had an
inferior outcome as compared to individual harbouring the 309TT
genotype (RFS; p=0.076, DSS; p=0.010). A similar finding was
recorded in the sub-cohort of patients harbouring wild-type TP53
(RFS; p=0.061, DSS; p=0.018; Figure 2B). No effect of MDM2
SNP309 genotype was recorded in the cohort of patients
harbouring TP53 mutations (RFS; p=0.815, DSS; p=0.419).
Stratifying patients according to treatment, similar to what was
recorded for TP53 mutation status; we found the MDM2 SNP309
309TG/GG genotypes to be associated with inferior RFS and
DSS in the paclitaxel (Figure 2C) but not in the epirubicin
(Figure 2D) cohort. This effect was recorded in the total cohort of
paclitaxel-treated patients (RFS; p=0.039, DSS; p=0.012,
Figure 2C) as well as in the sub-cohort of patients harbouring
wild-type TP53 (RFS; p=0.086, DSS; p=0.039).
Table 3. Distribution according to response to chemotherapy as initial and second treatment.
CR PR SD PD P
1 P
2
Response to epirubicin as initial treatment 3 (2.8%) 50 (46.7%) 44 (41.1%) 10 (9.3%)
Response to epirubicin as second treatment 1 (2.4%) 11 (26.8%) 27 (65.9%) 2 (4.9%) 0.512 0.028
Response to paclitaxel as initial treatment 5 (4.7%) 45 (42.5%) 44 (41.5%) 12 (11.3%)
Response to paclitaxel as second treatment 0 (0.0%) 7 (30.4%) 19 (63.3%) 4 (13.3%) 0.753 0.022
P
1, with regard to clinical response comparing CR/PR/SD versus PD; P
2, with regard to clinical response comparing.
CR/PR versus SD/PD.
doi:10.1371/journal.pone.0019249.t003
Table 2. Clinical response to paclitaxel in relation to different parameters.
Clinical response Statistical significance
CR (n=5) PR (n=45) SD (n=44) PD (n=12) P
1 P
2
TP53 mutations (n=25) 3 11 6 5 0.1487 0.4868
TP53 mutations affecting L2/L3 (n=12) 2 3 5 2 0.6235 0.6123
TP53 LOH (n=53) 2 23 24 7 0.7656 0.7509
TP53 SNP72 (n=34) 2 10 18 4 1 0.1464
CHEK2mutations (n=3) 3
MDM2 SNP309 (n=63) 3 28 23 9 0.3526 0.5123
MDM2 SNP309 (n=45)* 1 20 19 5 0.2286 0.3805
Clinical response in relation to different parameters. P
1, with regard to clinical response comparing CR/PR/SD versus PD; P
2, with regard to clinical response comparing
CR/PR versus PD;
*, In the subgroup of the patients revealing wild-type TP53.
doi:10.1371/journal.pone.0019249.t002
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19249Figure 1. Kaplan-Meier curves of relapse-free (left row) and disease-specific survival (right row). A, Difference between the treatment
arms; B, Difference in respect to TP53 mutation status; C, Difference in respect to TP53 mutation status in paclitaxel arm; D, Difference in respect to
TP53 mutation status in epirubicin arm.
doi:10.1371/journal.pone.0019249.g001
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19249Figure 2. Kaplan-Meier curves of relapse-free (left row) and disease-specific survival (right row). A, Difference in respect to MDM2
SNP309 status in sub-cohort of the patients harbouring wild-type TP53; B, Difference in respect to MDM2 SNP309 variants when TG and GG were
pooled in sub-cohort of the patients harbouring wild-type TP53; C, Difference in respect to MDM2 SNP309 variants when TG and GG were pooled in
paclitaxel arm. D; Difference in respect to MDM2 SNP309 variant when TG and GG were pooled in epirubicin arm.
doi:10.1371/journal.pone.0019249.g002
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Neither TP53 LOH nor Arg72Pro polymorphism status were
associated with RFS or DSS (Supporting Information Table S3).
In contrast, ER expression (defined as .10% of cells revealing
positive staining) was associated with improved RFS and DSS in
both cohorts together (RFS; p=0.070, DSS; p=0.005) and in the
epirubicin (RFS; p=0.021, DSS; p=0.008) but not in the
paclitaxel (RFS; p=0.906, DSS; p=0.196) arm (Supporting
Information Figure S2).
Multivariate analysis
Factors found to influence DSS in univariate analysis (TP53
mutation status, MDM2 genotype SNP309 (TT vs. TG/GG) and
ER expression) were evaluated in different models by multivariate
Cox regression analysis. The effects were analysed on both arms
combined to test for potential treatment interactions and in each
arm separately (for listing of parameters into the different models,
see Supporting Information Table S3).
Analysing both cohorts together, oestrogen receptor negativity
(RR=2.047, 95% CI=1.206–3.476, p=0.008) and MDM2
SNP309 TG/GG status (RR=2.039, 95% CI=1.152–3.610,
p=0.015) both predicted a poor outcome. Excluding oestrogen
receptor status from the analysis; MDM2 SNP309 TG/GG status
remained as a poor prognostic factor (RR=2.034, 95% CI=1.154–
3.585, p=0.014).
Analysing patients in the paclitaxel arm, only TP53 mutation
status (RR=2.319, 95% CI=1.068–5.037, p=0.033) remained as
a negative prognostic factor with a non-significant trend for
MDM2 TG/GG (RR=2.180, 95% CI=0.966–4.922, p=0.061)
independent of whether oestrogen receptor status was included in
the model.
With respect to the epirubicin arm, oestrogen receptor negativity
(RR=3.381, 95% CI=1.588–7.198, p=0.002) remained as a
prognostic factor in the multivariate analysis.
Discussion
Previously, we reported mutations affecting the L2/L3 DNA-
binding domain of p53 to be associated with lack of response to
weekly anthracycline- as well as mitomycin-containing chemo-
therapy [1,2]. More recently, we reported TP53 L2/L3 mutations,
but also non-sense mutations affecting the p53 upstream activator
Chk2, to be associated with resistance to primary treatment with
epirubicin [3]. Epirubicin acts by DNA intercalation. Treatment
with epirubicin will lead to DNA damage in the cell, subsequently
activating p53 leading to apoptotic cell death [21,22,23,24],
eventually senescence [25].
While TP53 mutations were associated with anthracycline
resistance [2,3], several tumors revealed chemoresistance despite
harbouring wild-type TP53. Thus, our recent finding that some of
these tumors harboured mutations in the CHEK2 gene (coding for
the Chk2 protein phosphorylating p53 in response to genotoxic
stress) indicates defects in the p53 pathway in addition to TP53
mutations. MDM2 plays a key role regulating p53 function
through direct binding, ubiquitination and degradation [26], and
MDM2 amplification has been considered an alternative way of
inactivating the p53 protein [8]. Due to recent findings of the
MDM2 SNP309T.G polymorphism enhancing MDM2 transcrip-
tion and its potential association to increased cancer risk [9], we
hypothesized that the MDM2 SNP309G genotype may be
associated with lack of response to an anthracycline regimen.
Further, to assess its potential prognostic role, we analyzed its
effect on long-term outcome in our two-arm study applying
epirubicin versus paclitaxel monotherapy. Notably, MDM2
genotype was not associated with response to neither epirubicin
nor paclitaxel treatment.
Taxanes prevent microtubule degradation, thus leading to cell
cycle distortion and apoptosis [27]. Conflicting data from
experimental studies have suggested a role for p53 executing
apoptosis in response to taxane treatment (5, 6, 21–27). Similar to
what has been recorded by others [4], we found TP53 mutations
not to predict resistance to paclitaxel treatment.
Surprisingly, we observed TP53 mutations to be associated with
an inferior long-term DSS among patients receiving paclitaxel but
not among patients having epirubicin as first-line therapy. TP53
mutations are known to be associated with a poor prognosis in
breast cancer patients in the absence of adjuvant therapy [28].
One potential explanation why TP53 mutation status was not
associated with prognosis despite predicting resistance to epir-
ubicin in this study could be the fact that patients responding
poorly to epirubicin were salvaged by second-line paclitaxel
treatment. While excluding patients having second-line treatment
from RFS and DSS analysis had marginal effect on the results
(data not shown), patients in need for second-line treatment are in
general, expected to have a particular poor prognosis; thus, the
possibility exist that these patients may have contributed to a
different outcome in case they had not receive salvage therapy.
Notably, among eight patients having a PD on epirubicin
treatment, four had a PR, while two obtained SD on subsequent
paclitaxel treatment (Supporting Information Table S2).
While TP53 mutation status was associated with prognosis among
patients having paclitaxel treatment upfront, this effect was found
better correlated to TP53 mutations in total as compared to mutations
affecting the L2/L3 domains, contrasting observations from previous
studies among patients not treated with chemotherapy [15] as well as
patients exposed to anthracycline therapy [2]. Notably, p53 is involved
in multiple functions including growth arrest, DNA repair, senescence
as well as apoptosis [29]. p53 is phosphorylated or acetylated at
multiple sites in response to different stimuli [24] and execute both
transcription dependent as well as independent functions [30]. Thus,
the possibility exist that p53 may influence prognosis in a different
manner among patients treated with paclitaxel as compared to
patients having either treatment with an anthracycline or no adjuvant
chemotherapy. A prognostic role for TP53 mutations restricted to the
paclitaxel-treated subgroup was indirectly supported by the observa-
tion of an inferior prognosis also among patients being either
heterozygote or homozygote for the MDM2 SNP 309G allele. This
effect of MDM2 SNP 309G status on prognosis was observed among
patients harbouring wild-type TP53 in their tumors only, consistent
with the biological activity of MDM2 inhibiting p53 activity [9,31,32].
Taken together, these observations supports the hypothesis that
enhanced MDM2 activity due to the 309G allele may substitute for
TP53 mutations with the two parameters conferring prognostic
impact within similar patient cohorts.
In summary, TP53 and CHEK2 mutations previously found
associated with lack of primary response does not significantly
affect long-term survival among patients receiving epirubicin as
first-line treatment. In contrast, TP53 mutations but also the
MDM2 promoter SNP309 G polymorphism influences long-term
survival among patients receiving paclitaxel with large primary
breast cancers.
Supporting Information
Figure S1 Kaplan-Meier curves of relapse-free and
disease-specific survival between treatment arms ac-
cording to TP53 mutation status. Kaplan-Meier curves of
relapse-free (left row) and disease specific survival (right row). A,
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19249Difference between the treatment arms among patients harbour-
ing TP53 mutations; B, Difference between the treatment arms
among patients harbouring wild-type TP53.
(TIF)
Figure S2 Kaplan-Meier curves of relapse-free and
disease-specific survival according to oestrogen recep-
tor status. Kaplan-Meier curves of relapse-free (left row) and
disease-specific survival (right row). A, Difference in survival
according to oestrogen receptor status (both treatment cohort
together); B, Difference in survival according to oestrogen receptor
status (epirubicin arm); C, Difference in survival according to
oestrogen receptor status (paclitaxel arm).
(TIF)
Table S1 Characteristics of TP53 mutants found in
paclitaxel cohort. Nucleotide number;
1, The bolded bases
indicate the base change;
2, Functional predictions derived from a
computer model that takes into account the 3D structure of WT
and mutant proteins and is trained on the trans activation dataset
from Kato et al. Mutations are classified as "functional" or "non-
functional". More details here. http://www-p53.iarc.fr/Help.
html#StructureClass; T, size or direct of the primary tumour;
N, spread to regional lymph nodes; M, distant metastasis; ‘, "F"
followed by a number indicates that the patient was free of disease
at that number of months of follow-up. "R" followed by a number
indicates that the patient was alive at that number of months of
follow-up but had suffered a relapse; "A" followed by a number
indicates that the patient was alive at that number of months of
follow-up. "D" followed by a number indicates that the patient
died at that number of months of follow-up; {, Characterised as a
mutation affecting L2/L3 domain, since it leads to truncation of
the protein and will mostly affect L2/L3 domain; AI, Allelic
imbalance; * One patient withdrew from the study and was
censored after 29 months follow up.
(XLS)
Table S2 Characteristics of patients switched therapy
regime.
(XLS)
Table S3 Effect of different factors on disease specific
survival by Cox regression univariate and multivariate
analysis.
(XLS)
Protocol S1 Detailed description of treatment protocol.
(DOC)
Method S1 TP53 gene copy number analysis.
(DOC)
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